Renin-Angiotensin System Modulation with Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults with COVID-19: Two Randomized Clinical Trials
Wesley H. Self, Matthew S. Shotwell, Kevin W. Gibbs, Marjolein De Wit, D. Clark Files, Michelle Harkins, Kristin M. Hudock, Lisa H. Merck, Ari Moskowitz, Krystle D. Apodaca, Aaron Barksdale, Basmah Safdar, Ali Javaheri, Jeffrey M. Sturek, Harry Schrager, Nicole Iovine, Brian Tiffany, Ivor S. Douglas, Joseph Levitt, Laurence W. BusseAdit A. Ginde, Samuel M. Brown, David N. Hager, Katherine Boyle, Abhijit Duggal, Akram Khan, Michael Lanspa, Peter Chen, Michael Puskarich, Derek Vonderhaar, Lokesh Venkateshaiah, Nina Gentile, Yves Rosenberg, James Troendle, Amanda J. Bistran-Hall, Josh Declercq, Robert Lavieri, Meghan Morrison Joly, Michael Orr, Jill Pulley, Todd W. Rice, Jonathan S. Schildcrout, Matthew W. Semler, Li Wang, Gordon R. Bernard, Sean P. Collins
Dive into the research topics of 'Renin-Angiotensin System Modulation with Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults with COVID-19: Two Randomized Clinical Trials'. Together they form a unique fingerprint.